Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Yiping Zou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2880-2147; OpenAlex author ID A5015201082. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: 4 papers · 2025: 4 papers · 2026: 1 paper

Papers 18

  1. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
  2. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  3. A Preoperative Model for Predicting Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2025.06.081↗
  4. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
  5. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Co-author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  6. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Co-author DOI 10.1016/j.surg.2024.07.047↗
  7. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  8. Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection. First author DOI 10.1186/s12957-024-03524-0↗
  9. Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0363↗
  10. A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2023.107589↗
  11. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective… Co-author DOI 10.1097/js9.0000000000000425↗
  12. Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2021/6682697↗
  13. Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.1155/2021/9949272↗
  14. Score for predicting overall survival in pancreatic adenocarcinoma patients with positive lymph nodes after surgery: a novel nomogram-based risk assessment. First author DOI 10.21037/gs-20-597↗
  15. Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study. Co-author PMID 34249426↗
  16. Down-regulated lncRNA SBF2-AS1 in M2 macrophage-derived exosomes elevates miR-122-5p to restrict XIAP, thereby limiting pancreatic cancer development. Co-author DOI 10.1111/jcmm.15125↗
  17. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1186/s13014-020-01511-9↗
  18. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway. Co-author DOI 10.1186/s13046-019-1313-x↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 9 shared papers, 2023–2026 · strength 1.72
  2. Yuexiang Liang · 6 shared papers, 2023–2025 · strength 1.35
  3. Song Gao · 6 shared papers, 2023–2025 · strength 1.29
  4. Shaofei Chang · 5 shared papers, 2023–2025 · strength 1.07
  5. Jun Yu · 5 shared papers, 2024–2026 · strength 0.97
  6. Xiuchao Wang · 5 shared papers, 2023–2025 · strength 0.93
  7. Tiansuo Zhao · 5 shared papers, 2023–2025 · strength 0.93
  8. Yongjie Xie · 5 shared papers, 2023–2025 · strength 0.88
  9. Quan Man · 3 shared papers, 2023–2025 · strength 0.62
  10. Baohua Hou · 5 shared papers, 2020–2021 · strength 0.58
  11. Shiye Ruan · 3 shared papers, 2020–2025 · strength 0.54
  12. Chongbiao Huang · 3 shared papers, 2024–2025 · strength 0.53
  13. Tianxing Zhou · 3 shared papers, 2023–2025 · strength 0.51
  14. Song Gao · 2 shared papers, 2024–2025 · strength 0.44
  15. Ning Shi · 3 shared papers, 2020–2021 · strength 0.38
  16. Yukuan Feng · 2 shared papers, 2025 · strength 0.37
  17. Chuntao Gao · 2 shared papers, 2023–2024 · strength 0.35
  18. Chuanzhao Zhang · 3 shared papers, 2021 · strength 0.34
  19. Zhenchong Li · 3 shared papers, 2021 · strength 0.34
  20. Hongkai Zhuang · 3 shared papers, 2021 · strength 0.34
  21. Shanzhou Huang · 3 shared papers, 2021 · strength 0.34
  22. Zuyi Ma · 3 shared papers, 2021 · strength 0.34
  23. Zixuan Zhou · 3 shared papers, 2021 · strength 0.34
  24. Bowen Huang · 3 shared papers, 2021 · strength 0.34
  25. Haosheng Jin · 2 shared papers, 2020–2021 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.